Nothing Special   »   [go: up one dir, main page]

WO2003024457A1 - Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie - Google Patents

Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie Download PDF

Info

Publication number
WO2003024457A1
WO2003024457A1 PCT/JP2002/007712 JP0207712W WO03024457A1 WO 2003024457 A1 WO2003024457 A1 WO 2003024457A1 JP 0207712 W JP0207712 W JP 0207712W WO 03024457 A1 WO03024457 A1 WO 03024457A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
remedy
cardiopathy
medicinal composition
prevention
Prior art date
Application number
PCT/JP2002/007712
Other languages
English (en)
French (fr)
Inventor
Yoshinori Toshima
Asako Hitomi
Shin-Ichi Satoh
Ichiro Ikegaki
Original Assignee
Asahi Kasei Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Kabushiki Kaisha filed Critical Asahi Kasei Kabushiki Kaisha
Priority to US10/488,699 priority Critical patent/US20040242565A1/en
Priority to DE60227679T priority patent/DE60227679D1/de
Priority to EP02751784A priority patent/EP1426051B1/en
Priority to JP2003528553A priority patent/JP4194095B2/ja
Publication of WO2003024457A1 publication Critical patent/WO2003024457A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2002/007712 2001-09-11 2002-07-30 Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie WO2003024457A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/488,699 US20040242565A1 (en) 2001-09-11 2002-07-30 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
DE60227679T DE60227679D1 (de) 2001-09-11 2002-07-30 Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen
EP02751784A EP1426051B1 (en) 2001-09-11 2002-07-30 Medicinal composition for prevention of or treatment for cerebrovascular disorder
JP2003528553A JP4194095B2 (ja) 2001-09-11 2002-07-30 脳血管障害、心疾患の予防・治療用医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-274846 2001-09-11
JP2001274846 2001-09-11

Publications (1)

Publication Number Publication Date
WO2003024457A1 true WO2003024457A1 (fr) 2003-03-27

Family

ID=19099815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007712 WO2003024457A1 (fr) 2001-09-11 2002-07-30 Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie

Country Status (6)

Country Link
US (1) US20040242565A1 (ja)
EP (1) EP1426051B1 (ja)
JP (1) JP4194095B2 (ja)
AT (1) ATE401082T1 (ja)
DE (1) DE60227679D1 (ja)
WO (1) WO2003024457A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106325A1 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097583A1 (en) * 2002-02-14 2004-05-20 Hans-Jochen Lang Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders
SI1507558T1 (sl) * 2002-05-17 2011-12-30 Novartis Pharma Ag Farmacevtski sestavek, ki obsega reninski inhibitor, blokator kalcijevega kanala in diuretik
US20040168951A1 (en) * 2003-02-27 2004-09-02 Mackie Robert W. Method and system for self administration of medications
EP1710243A4 (en) * 2004-01-29 2009-09-23 Asahi Kasei Pharma Corp THERAPEUTIC AGENT FOR VASOSPASM ACCOMPANYING A BRIDGE OPERATION
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
US20080175831A1 (en) * 2006-12-21 2008-07-24 Macknik Stephen L Neuroprotection by blood flow stabilization
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer
US8236346B2 (en) * 2007-10-05 2012-08-07 Alzheimer's Institute of America, Inc Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
CN101969955A (zh) * 2008-01-31 2011-02-09 莫纳什大学 治疗血栓栓塞疾病的方法
FR2927538B1 (fr) * 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
ES2330404B1 (es) * 2008-05-19 2010-09-22 Universidad De Barcelona Solucion acuosa para la preservacion de tejidos y organos.
KR101721068B1 (ko) * 2015-01-30 2017-03-29 고려대학교 산학협력단 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) * 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
WO1993023082A1 (en) * 1992-05-13 1993-11-25 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
WO1996005838A2 (de) * 1994-08-25 1996-02-29 Hoechst Aktiengesellschaft Kombinationspräparat zur anwendung bei immunologischen erkrankungen
WO1996025933A2 (en) * 1995-02-22 1996-08-29 Takeda Chemical Industries, Ltd. Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks
JPH107590A (ja) * 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
WO2002009761A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP2002226374A (ja) * 2001-01-31 2002-08-14 Asahi Kasei Corp 狭心症治療用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
PT885888E (pt) * 1996-02-02 2003-12-31 Western Therapeutics Inst D Derivados e farmacos de isoquinolina

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) * 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
WO1993023082A1 (en) * 1992-05-13 1993-11-25 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
WO1996005838A2 (de) * 1994-08-25 1996-02-29 Hoechst Aktiengesellschaft Kombinationspräparat zur anwendung bei immunologischen erkrankungen
WO1996025933A2 (en) * 1995-02-22 1996-08-29 Takeda Chemical Industries, Ltd. Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks
JPH107590A (ja) * 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
WO2002009761A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP2002226374A (ja) * 2001-01-31 2002-08-14 Asahi Kasei Corp 狭心症治療用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WATARU MUKAI ET AL.: "Koreisha ya shinkino teika o gappei shita kyoshinsho no chiryo no kihon", MEDICINA, vol. 31, no. 13, 1994, pages 2571 - 2573, XP002958942 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106325A1 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine

Also Published As

Publication number Publication date
JP4194095B2 (ja) 2008-12-10
EP1426051A4 (en) 2005-06-15
US20040242565A1 (en) 2004-12-02
EP1426051A1 (en) 2004-06-09
JPWO2003024457A1 (ja) 2004-12-24
EP1426051B1 (en) 2008-07-16
DE60227679D1 (de) 2008-08-28
ATE401082T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
WO2003024457A1 (fr) Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MXPA04002035A (es) Derivados de 1, 8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados.
CA2358998A1 (en) Substituted bicyclic derivatives useful as anticancer agents
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
CA2333703A1 (en) Isothiazole derivatives useful as anticancer agents
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
CA2179008A1 (en) 5-(2-Imidazolinylamino)Benzimidazole Derivatives, Their Preparation and Their Use as Alpha-2 Adrenoceptor Agonists
EP1396493A4 (en) HETEROCYCLIC COMPOUNDS
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
CA2382919A1 (en) Bicyclic imidazo-3-yl-amine derivatives
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
CA2468649A1 (en) Adenosine a2a receptor antagonists
CA2308677A1 (en) 4'-c-ethynyl purine nucleoside compounds
WO2000023057A3 (en) Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
CA2336412A1 (en) Medicament for treatment of diabetes
CA2469592A1 (en) Hiv integrase inhibitors
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
HK1054692A1 (en) Composition containing an angiotensin ii receptor antagonist and a diuretic and its use for the treatment of hypertension
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
IL159412A0 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
JP2003522768A5 (ja)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003528553

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002751784

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002751784

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10488699

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002751784

Country of ref document: EP